EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing of drugs for combined treatment of COVID-19 cytokine storm using machine learning

Maanaskumar R Gantla, Igor F Tsigelny, Valentina L Kouznetsova

Medicine in Drug Discovery · 2023-02 · 17 · 100148

DOI: 10.1016/j.medidd.2022.100148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicine in Drug Discovery, 2023-02. Verfasst von Maanaskumar R Gantla und 2 weiteren Autor:innen. Beteiligte Einrichtung: MAP Program, UC San Diego, Calif, USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) induced cytokine storm is the major cause of COVID-19 related deaths. Patients have been treated with drugs that work by inhibiting a specific protein partly responsible for the cytokines production. This approach provided very limited success, since there are multiple proteins involved in the complex cell signaling disease mechanisms. We targeted five proteins: Angiotensin II receptor type 1 (AT1R), A disintegrin and metalloprotease 17 (ADAM17), Nuclear Factor‑Kappa B (NF‑κB), Janus kinase 1 (JAK1) and Signal Transducer and Activator of Transcription 3 (STAT3), which are involved in the SARS‑CoV‑2 induced cytokine storm pathway. We developed machine-learning (ML) models for these five proteins, using known active inhibitors. After developing the model for each of these proteins, FDA-approved drugs were screened to find novel therapeutics for COVID‑19. We identified twenty drugs that are active for four proteins with predicted scores greater than 0.8 and eight drugs active for all five proteins with predicted scores over 0.85. Mitomycin C is the most active drug across all five proteins with an average prediction score of 0.886. For further validation of these results, we used the PyRx software to conduct protein-ligand docking experiments and calculated the binding affinity. The docking results support findings by the ML model. This research study predicted that several drugs can target multiple proteins simultaneously in cytokine storm-related pathway. These may be useful drugs to treat patients because these therapies can fight cytokine storm caused by the virus at multiple points of inhibition, leading to synergistically effective treatments.

Schlagwörter

Stichwörter der Autor:innen

1D 2D 3D, one- two- three-dimensionalADAM17, A disintegrin and metalloprotease 17ARDS, acute respiratory distress syndromeAT1R, Angiotensin II receptor type 1AUROC, Area under receiver operator characteristic curveCOVID-19COVID-19, coronavirus disease 2019CRS, cytokine release syndromeCXCL10, CXC-chemokine ligand 10DockingFDA, Food and Drug AdministrationG-CSF, granulocyte colony stimulating factorIC50, half maximal inhibitory concentrationICU, intensive care unitIL, interleukin

Autor:innen und Institutionen

  • MAP Program, UC San Diego, Calif, USA.
  • San Diego Supercomputer Center, UC San Diego, Calif, USA.
  • BiAna, La Jolla, Calif, USA.
  • Dept. of Neurosciences, UC San Diego, Calif, USA.

Zitieren

APA

Gantla, M. R., Tsigelny, I. F., & Kouznetsova, V. L. (2023). Repurposing of drugs for combined treatment of COVID-19 cytokine storm using machine learning. Medicine in Drug Discovery, 17, 100148. https://doi.org/10.1016/j.medidd.2022.100148

Vancouver

Gantla MR, Tsigelny IF, Kouznetsova VL. Repurposing of drugs for combined treatment of COVID-19 cytokine storm using machine learning. Medicine in Drug Discovery. 2023;17:100148. doi:10.1016/j.medidd.2022.100148

BibTeX
@article{Gantla2023,
  author = {Gantla, Maanaskumar R and Tsigelny, Igor F and Kouznetsova, Valentina L},
  title = {Repurposing of drugs for combined treatment of COVID-19 cytokine storm using machine learning},
  journal = {Medicine in Drug Discovery},
  year = {2023},
  volume = {17},
  pages = {100148},
  doi = {10.1016/j.medidd.2022.100148}
}
Kostenlos starten →